Aurobindo Pharma Limited (NSE:AUROPHARMA)
1,105.50
+9.80 (0.89%)
Sep 18, 2025, 11:30 AM IST
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 78.68B INR in the quarter ending June 30, 2025, with 3.98% growth. This brings the company's revenue in the last twelve months to 320.25B, up 7.76% year-over-year. In the fiscal year ending March 31, 2025, Aurobindo Pharma had annual revenue of 317.24B with 9.39% growth.
Revenue (ttm)
320.25B
Revenue Growth
+7.76%
P/S Ratio
1.99
Revenue / Employee
11.56M
Employees
27,707
Market Cap
636.38B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 317.24B | 27.22B | 9.39% |
Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
Mar 31, 2021 | 247.75B | 16.76B | 7.26% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |
Aurobindo Pharma News
- 7 days ago - Why are Aurobindo Pharma shares up 5% today? Know More - Business Upturn
- 10 days ago - Top stocks to watch today, September 8: BHEL, NTPC Green, Adani Green, Aurobindo Pharma and more - Business Upturn
- 12 days ago - Aurobindo Pharma’s Unit-XII receives US FDA Form 483 with 8 observations - Business Upturn
- 23 days ago - Aurobindo Pharma’s CuraTeQ Biologics secures UK MHRA approval for biosimilar Dazublys - Business Upturn
- 4 weeks ago - Aurobindo Pharma denies media reports on $5.5 billion Zentiva buyout - Business Upturn
- 5 weeks ago - Pharma sector stocks in focus: Citi flags competitive setback for Dr Reddy’s, Aurobindo in iron sucrose opportunity - Business Upturn
- 6 weeks ago - Raymond to Dr Reddy's: Textiles, pharma stocks bear tariffs brunt - The Times of India
- 6 weeks ago - Aurobindo Pharma share: Macquarie downgrades to underperform, flags US business concerns - Business Upturn